Home > Insider Trading > Filing (0000904454-16-001170)

Filing Details

Accession Number:: 0000904454-16-001170
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2016-04-21 16:57:05
Reporting Period:: 2016-04-19

Filing Date:: 2016-04-21
Accepted Time:: 2016-04-21 16:57:05
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1403708	Evoke Pharma Inc	EVOK	()	DE

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1013425	I Jesse Treu	C/O Domain Associates, Llc One Palmer Square Princeton NJ 08542	No	No	Yes	No
1024000	C James Blair	C/O Domain Associates, Llc One Palmer Square Princeton NJ 08542	No	No	Yes	No
1196863	Nicole Vitullo	C/O Domain Associates, Llc One Palmer Square Princeton NJ 08542	No	No	Yes	No
1207786	H Brian Dovey	C/O Domain Associates, Llc One Palmer Square Princeton NJ 08542	No	No	Yes	No
1354718	K Brian Halak	C/O Domain Associates, Llc One Palmer Square Princeton NJ 08542	No	No	Yes	No
1374150	P L Vii Parters Domain	C/O Domain Associates, Llc One Palmer Square Princeton NJ 08542	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2016-04-19	37,054	$5.36	959,922	No	4	S	Direct
Common Stock	Disposition	2016-04-20	4,424	$5.29	955,498	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct
No	4	S	Direct

Footnotes

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.20 to $5.51. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
The securities reported as directly beneficially owned by the Reporting Person may be deemed to be indirectly beneficially owned by each of the Reporting Owners listed below, each of whom is a managing member of One Palmer Square Associates VII, LLC ("OPSA VII"), the sole general partner of the Reporting Person. Pursuant to Instruction 4(b)(iv) of Form 4, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by the Reporting Person, however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her.
As managing members of OPSA VII, which is also the sole general partner of DP VII Associates, L.P. each Reporting Owner listed below may also be deemed to indirectly beneficially own 16,290 shares of Common Stock held by DP VII Associates, L.P. Pursuant to Instruction 4(b)(iv) of Form 4, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by DP VII Associates, L.P., however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her.
As managing members of Domain Associates, LLC, each Reporting Owner listed below may also be deemed to indirectly beneficially own 5,250 shares of Common Stock held by Domain Associates, LLC. Pursuant to Instruction 4(b)(iv) of Form 4, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by Domain Associates, LLC, however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.20 to $5.36. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.